progression on CDR-G
Fig. 3 · Panel CDR-G_progression
Panel CDR-G_progression 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jennifer A Zimmer, John R Sims, Cynthia D Evans, Emel Serap Monkul Nery, Hong Wang, Alette M Wessels, Giulia Tronchin, Shoichiro Sato, Lars Lau Raket, Scott W Andersen, Christophe Sapin, Marie-Ange Paget, Ivelina Gueorguieva, Paul Ardayfio, Rashna Khanna, Dawn A Brooks, Brandy R Matthews, Mark A Mintun, Alzheimer’s Disease Neuroimaging Initiative
J Prev Alzheimers Dis 13(2) 100446
BACKGROUND: Donanemab significantly slowed clinical progression in participants with early symptomatic Alzheimer's disease (AD) during the 76-week placebo-controlled period of TRAILBLAZER-ALZ 2. METHODS: Participants who completed the placebo-controlled period were eligible for the 78-week, double-blind, long-term extension (LTE). Early-start participants were randomized to donanemab in the placebo-controlled period. Delayed-start participants (randomized to placebo) started donanemab in the LTE. Participants who met amyloid treatment course completion criteria were switched to placebo. An external control cohort comprised participants from the AD Neuroimaging Initiative (ADNI). RESULTS: At 3 years, donanemab slowed disease progression on the Clinical Dementia Rating Scale (CDR)-Sum of Boxes (CDR-SB) in early-start participants versus a weighted ADNI control (-1.2 points; 95 % confidence interval [CI], -1.7, -0.7). Seventy-six weeks after initiating donanemab, delayed-start participants also demonstrated slower CDR-SB progression versus a weighted ADNI control (-0.8 points; 95 % CI, -1.3, -0.3). Participants who completed treatment by 52 weeks demonstrated similar slowing of CDR-SB progression at 3 years. Compared with delayed-start participants, early-start participants demonstrated a significantly lower risk of disease progression on the CDR-Global over 3 years (hazard ratio=0.73; p < 0.001). In both groups, >75 % of participants assessed by positron emission tomography 76 weeks after starting donanemab achieved amyloid clearance (<24.1 Centiloids). The addition of LTE data to prior modeling predicted a median reaccumulation rate of 2.4 Centiloids/year. No new safety signals were observed compared to the established donanemab safety profile. CONCLUSIONS: Over 3 years, donanemab-treated participants with early symptomatic AD demonstrated increasing clinical benefits and a consistent safety profile, with limited-duration dosing. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT04437511.
1 个 Figure · 1 个 KM 面板
Fig. 3 CDR-G hazard progression: early-start vs delayed-start treatment with donanemab. Early-start participants showed a 27 % reduced risk of progressing to the next clinical stage of the disease versus delayed-start participants. a Hazard ratio, 95 % CI, and p value were calculated using a Cox proportional hazards model. The model was stratified by pooled investigator and baseline tau level and included baseline covariates of age, CDR-G score, and acetylcholinesterase inhibitor/memantine use. CDR-G: Clinical Dementia Rating Scale–Global; CI: confidence interval. Copyright © 2025 Eli Lilly and Company. All rights reserved. Permission for any use should be sought from Eli Lilly and Company.
Fig. 3 · Panel CDR-G_progression
Panel CDR-G_progression 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。